Anja Krammer
About Anja Krammer
Independent director of Vivos Therapeutics (VVOS), age 58, on the Board since June 2020. CEO of Turn Biotechnologies since early 2020; prior roles span public-company leadership and commercialization in medtech and pharma. Education: BAIS (Marketing/Management), University of South Carolina, and International Trade Certificate, University of Paris–Sorbonne. Board affirms her independence; credentials cited include CEO experience, capital markets leadership, startup execution, and pharma sector expertise .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BioPharmX (NYSE IPO) | Co-founder; President; Secretary; Director | 2013–2018 | Led IPO onto NYSE; specialty pharmaceutical commercialization |
| MBI, Inc. (consulting) | Principal/Founder | Began Jan 1998 | Management consulting across healthcare/technology |
| Reliant Technologies (aesthetic medicine) | VP Global Marketing | Apr 2006–Aug 2008 | Venture-backed commercialization and global marketing leadership |
| Medtronic | Sr. Director, Strategic Marketing | Apr 2004–Apr 2006 | Strategic marketing in medtech |
| Getronics (IT services) | VP, Solutions Marketing | Dec 2000–Sep 2001 | Solutions marketing; global IT services |
| Acterna (Itronix Division, optical communications) | VP, Indirect Channel Sales & Worldwide Industry Partnership Marketing | Apr 1999–Dec 2000 | Channel development and industry partnerships |
| Tektronix (Color Printing & Imaging) | Director, Worldwide Marketing & Communications | Oct 1997–Apr 1999 | Global marketing communications |
| KeyTronic (computer equipment) | Director, Worldwide Sales & Marketing | Oct 1995–Oct 1997 | Global sales & marketing |
External Roles
| Organization | Role | Public/Private | Tenure |
|---|---|---|---|
| Turn Biotechnologies | Chief Executive Officer; Director | Private | Early 2020–present |
| Pixium-Vision SA (EURONEXT: PIX/ALPIX) | Director | Public | Disclosed in prior proxies (2023/2024) |
Board Governance
- Independence: Board determined Krammer is independent under Nasdaq rules .
- Board structure: 6 directors; CEO also Chairman; no Lead Independent Director; executive sessions held among independents; Board reviews leadership structure periodically .
- Committee assignments:
- Audit Committee member (Chair: Leonard J. Sokolow; audit committee financial expert) .
- Nominating & Corporate Governance Committee member (Chair: Dr. Matthew Thompson) .
- Not on Compensation Committee (Chair: Mark F. Lindsay) .
- Attendance: In FY 2024, Board met 7x; Audit 5x; Compensation 7x; Nominating did not meet; directors attended 97% of meetings on committees served; all directors attended the Nov 26, 2025 annual meeting .
| Committee | Membership | Chair | FY 2024 Meetings |
|---|---|---|---|
| Audit | Krammer; Sokolow; Green | Sokolow | 5 |
| Compensation | Lindsay; Thompson; Green | Lindsay | 7 |
| Nominating & Governance | Thompson; Krammer; Sokolow | Thompson | 0 |
Fixed Compensation
- Program: Non-employee directors receive $48,000 annual cash retainer; committee chairs $10,000; committee members $5,000; no meeting fees; equity-plan based awards may be granted .
| Metric | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Cash Retainer & Committee Fees ($) | $33,833 | $58,000 | $58,000 |
| Stock Awards ($) | $0 | $0 | $0 |
| Option Awards ($) | $9,766 | $0 | $7,840 |
| Total ($) | $43,599 | $58,000 | $65,840 |
Notes:
- Krammer’s FY 2023 cash reflects $48k base + $5k per committee (Audit; Nominating) = $58k; no options in 2023; consistent with program .
Performance Compensation
- Director equity awards: Options recorded in FY 2024 ($7,840 fair value); proxy describes equity-plan awards but does not detail director-specific performance metrics or vesting schedules; performance conditions disclosed in proxy apply to executive options, not directors .
| Component | Metric linkage | Vesting/Terms | Disclosure |
|---|---|---|---|
| Director equity awards (options) | Not specified for directors | Not specified for directors | Proxy lists option grant values; no director metrics detailed |
Other Directorships & Interlocks
| Company | Role | Committee Roles | Interlock/Conflict Notes |
|---|---|---|---|
| Turn Biotechnologies | Director | Not disclosed | No VVOS-related party transactions disclosed; independence affirmed |
| Pixium-Vision SA | Director | Not disclosed | Historical external public board; not disclosed in 2025 proxy |
Expertise & Qualifications
- Board cites her CEO and director experience, capital markets leadership, startup execution, and pharma industry background as qualifications .
- Education and long tenure across medtech, pharma, and technology firms support governance depth .
Equity Ownership
- Beneficial ownership includes options exercisable within 60 days; less than 1% ownership throughout; shares outstanding context provided for each year .
| Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Beneficial ownership (shares) | 69,167 (includes options exercisable within 60 days; excludes 7,500 unvested) | 6,067 (includes options per table; percent <1%) | 6,400 (includes options exercisable within 60 days; percent <1%) |
| Ownership % of outstanding | <1% | <1% | <1% |
| Exercisable vs unexercisable | 69,167 exercisable; 7,500 unvested excluded | Not detailed | 6,400 exercisable; unvested not detailed |
Pledging/Hedging and Guidelines:
- No pledging/hedging disclosures for directors; proxy does not present director stock ownership guidelines; Nominating & Governance oversees director compensation .
Governance Assessment
- Strengths: Independent director serving on Audit and Nominating; high attendance (97%); Board conducts executive sessions; Audit Committee chaired by an audit committee financial expert; robust related-party review policy; no related-party transactions reported, supporting conflict-free oversight .
- Watch items: CEO is also Chairman and Board lacks a Lead Independent Director—oversight risk mitigated by five independent directors and executive sessions but remains a structure consideration for investors . Equity plan share reserve expansion from 1.6M to 4.1M (pending shareholder approval) increases potential dilution; assess alignment through actual director ownership and grant practices .
- Compensation alignment: Director cash increased to $58k with committee memberships; modest option awards in 2024 ($7,840). Proxy does not disclose director-specific performance metrics for equity; focus on audit/nominating contributions rather than pay-for-performance signals for directors .
- Policies: Updated Insider Trading Policy (pre-clearance; trading windows) and clawback policy apply to officers (not directors), reinforcing control environment for management; governance committees oversee director compensation and compliance .